82
1
11
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39185 |
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated |
||
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is a phosphorylated peptide derived from an EGFR substrate. It serves as a valuable tool for quantifying phosphorylated substrates in screening EGFR Kinase inhibitors. | |||
T21761 |
HNMPA
|
IGF-1R | Tyrosine Kinase/Adaptors |
HNMPA 是膜不可渗透的胰岛素受体酪氨酸激酶 (insulin receptor tyrosine kinase) 抑制剂。HNMPA 可以抑制人胰岛素受体的酪氨酸和丝氨酸自磷酸化。HNMPA 对环 AMP 依赖性蛋白激酶或蛋白激酶 C 活性没有影响。 | |||
T36287 |
Pirtobrutinib
|
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inhibits various BTK C481 substitution mutations, leading to tumor regression in BTK-dependent lymphoma tumors in mouse xenograft models. Furthermore, Pirtobrutinib exhibits remarkable selectivity for BTK, with more than a 300-fold difference compared to 370 other kinases tested. Notably, at a concentration of 1 μM, Pirtobrutinib demonstrat... | |||
T14765 |
BOS-172722
|
Kinesin | Cytoskeletal Signaling |
BOS-172722 是一种单极纺锤体 1 (MPS1) 检查点抑制剂,对MPS1 (1 mM ATP) 和P-MPS1 的IC50值分别为 11 nM 和 63 nM。它可研究多种乳腺癌。 | |||
T14137 |
AG 1295
|
PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
AG 1295 是选择性血小板衍生生长因子受体酪氨酸激酶抑制剂。它能抑制 PDGFR 的自磷酸化,对 EGF 受体的自磷酸化无影响。 | |||
T1770 |
GNE-9605
|
LRRK2 | Autophagy |
GNE-9605 是一个高效,选择性和能脑渗透的LRRK2抑制剂,IC50为19 nM。 | |||
T22396 |
PF-6274484
PF 6274484 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PF-6274484 是一种EGFR 抑制剂,对于 EGFR-L858R/T790M 和 WT-EGFR 的 Ki 值分别为 0.14 和 0.18 nM。它在 H1975 肿瘤细胞和 A549 肿瘤细胞中抑制EGFR-L858R/T790M 自身磷酸化和EGFR-WT,IC50分别为6.6和 5.8 nM。 | |||
T2694 |
KN-62
|
CaMK; P2X Receptor; Autophagy | Autophagy; Membrane transporter/Ion channel; Neuroscience |
KN-62 是一种选择性的、可逆的钙调蛋白依赖性蛋白激酶 II (CaMK-II) 抑制剂,直接与 CaMK-II 酶的钙调蛋白结合位点结合,对大鼠脑 CaMK-II 的IC50值为 0.9 μM。它是非竞争性的P2X7受体拮抗剂,IC50约为 15 nM。 | |||
T38562 |
AKN-028
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
AKN-028 是酪氨酸激酶 FLT3的抑制剂,可剂量依赖性的诱导 FLT3的自磷酸化。 | |||
T4014 |
CP-724714
CP724714,CP 724714 |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
CP-724714 (CP724714) 是一种高效、选择性口服活性的 ErbB2 (HER2)酪氨酸激酶抑制剂,IC50为 10 nM。它能抑制完整细胞中 ErbB2 受体的自磷酸化,具有抗肿瘤活性。它对 EGFR 激酶有明显的选择性,IC50值为6400 nM。 | |||
T2085 |
PQ401
IGF-1R Inhibitor II |
Apoptosis; IGF-1R | Apoptosis; Tyrosine Kinase/Adaptors |
PQ401 (IGF-1R Inhibitor II) 是一种IGF-IR 抑制剂。在 MCF-7 细胞中,它抑制 IGF-I 刺激的 IGF-IR 自磷酸化,可有效抑制 IGF-I 刺激的 MCF-7 细胞生长。它诱导 caspase 介导的细胞凋亡,有用于乳腺癌和其他对 IGF-I 敏感的癌症的研究潜力。 | |||
T5168 |
EGFR-IN-12
EGFR Inhibitor |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-12 (EGFR Inhibitor) 是一种 4,6-二取代的嘧啶,可诱导细胞凋亡,具有抗肿瘤活性。它是ATP 竞争性,不可逆且高度选择性的EGFR 抑制剂,IC50为 21 nM。它对EGFR 的选择性高于 HER4 和 55种其他激酶。它还抑制突变型EGFRL858R 和EGFRL861Q,IC50分别为 63 nM 和 4 nM。 | |||
T7673 |
ATH686
ATH 686 |
Apoptosis; FLT | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
ATH686 是一种选择性的,ATP 竞争性的FLT3抑制剂,具有抗白血病作用。它靶向突变 FLT3 蛋白激酶活性,并通过诱导凋亡和抑制细胞周期来抑制具有 FLT3 突变的细胞的增殖。 | |||
T3058 |
(Z)-SMI-4a
TCS PIM-1 4a,SMI-4a |
Pim | Chromatin/Epigenetic; JAK/STAT signaling |
(Z)-SMI-4a (TCS PIM-1 4a) 是一种选择性的,细胞可渗透的且具有 ATP 竞争性的 Pim-1抑制剂,IC50为 24 μM,Ki 为 0.6 μM。它还抑制 Pim-2,IC50为 100 μM,具有抗癌活性。 | |||
T9564 |
IRE1α kinase-IN-1
|
IRE1 | Cell Cycle/Checkpoint |
IRE1α kinase-IN-1 是IRE1α 的选择性抑制剂(IC50为 77 nM),对 IRE1α 的选择性高于 IRE1β 亚型 100 倍。它抑制内质网诱导的 IRE1α 寡聚和自磷酸化,并抑制 IRE1α RNase 活性 (IC50=80 nM)。 | |||
T8330 |
BIO-013077-01
6-(3-(6-甲基吡啶-2-基)-1H-吡唑-4-基)喹噁啉 |
TGF-beta/Smad | Stem Cells |
BIO-013077-01 是吡唑类TGF-β抑制剂。 | |||
T8976 |
PD-089828
|
EGFR; FGFR; PDGFR; Src | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PD-089828 是受体酪氨酸激酶 FGFR1、PDGFRβ 和 EGFR 的竞争性抑制剂,IC50分别为0.15、1.76 和 5.47 µM。它也是非受体酪氨酸激酶 c-Src 的非竞争性抑制剂,IC50 为 0.18 µM。 | |||
T2655 |
CEP-37440
CEP37440 |
FAK; ALK | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
CEP-37440 是一种新型的 FAK (IC50:2.3 nM) 和 ALK (IC50:120 nM) 双重抑制剂。 | |||
T4327 |
Prexasertib dihydrochloride
LY2606368 (dihydrochloride),Prexasertib HCl,LY2606368 |
Apoptosis; Chk; S6 Kinase | Apoptosis; Cell Cycle/Checkpoint; MAPK; PI3K/Akt/mTOR signaling |
Prexasertib dihydrochloride (LY2606368) 是一种选择性的,ATP 竞争性的细胞周期检测点激酶 1 抑制剂,Ki 为 0.9 nM,IC50为 <1 nM。它抑制 CHK2(IC50=8 nM) 和 RSK1 (IC50=9 nM)。它引起双链 DNA 断裂和复制突变,导致细胞凋亡,有抗肿瘤活性。 | |||
T4205 |
AG-494
Tyrphostin AG-494,AG 494,Tyrphostin B48 |
EGFR; CDK | Angiogenesis; Cell Cycle/Checkpoint; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
AG-494 (Tyrphostin B48) 是一种高效、选择性的 EGFR 酪氨酸激酶抑制剂,IC50为0.7 μM。它阻断 Cdk2 的激活并抑制 EGF 依赖的 DNA 合成。它抑制 EGFR、ErbB2、HER1-2 和 PDGF-R 的自磷酸化,IC50为 1.1、39、45 和 6 μM。 | |||
T23127 |
PD-161570
PD 161570 |
EGFR; FGFR; PDGFR; Src | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PD-161570 是一种有效的 ATP 竞争性人 FGF-1 受体抑制剂,IC50 为 39.9 nM,Ki 为 42 nM。它还是骨形态发生蛋白 (BMPs) 和TGF-β信号抑制剂。它抑制PDGF 刺激的自磷酸化和FGF-1受体磷酸化,IC50分别为 450 和 622 nM。它抑制 PDGFR、EGFR 和 c-Src 酪氨酸激酶,IC50 值分别为 310、240 和 44 nM。 | |||
T4310 |
Prexasertib
5-[[5-[2-(3-氨基丙氧基)-6-甲氧基苯基]-1H-吡唑-3-基]氨基]-2-吡嗪甲腈,LY2606368 |
Apoptosis; Chk | Apoptosis; Cell Cycle/Checkpoint |
Prexasertib (LY2606368) 是一种具有潜在抗肿瘤活性的检查点激酶 1 抑制剂。它可引起双链 DNA 断裂和复制突变,导致细胞凋亡。 | |||
T0373 |
Erlotinib
OSI-744,NSC 718781,CP358774,埃罗替尼,R1415 |
EGFR; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Erlotinib (CP358774) 是一种 EGFR 一代抑制剂,抑制 EGFR 19 Del 和 L858R 突变。Erlotinib 具有抗肿瘤活性,用于治疗 EGFR 突变的非小细胞肺癌。Erlotinib 用药会产生 EGFR C797S 耐药突变。 | |||
T1667 |
Tandutinib
MLN518,CT53518,NSC726292,坦度替尼 |
Apoptosis; FLT; CSF-1R; PDGFR; Src; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Tandutinib (CT53518) 是一种选择性 FLT3抑制剂,其 IC50为 0.22 μM。它还抑制c-Kit 和PDGFR,其IC50分别为 0.17 μM 和 0.20 μM。它可穿透血脑屏障,用于急性骨髓性白血病。 | |||
T2610 |
BMS-599626
AC480 |
EGFR; MEK; HER; Src | Angiogenesis; JAK/STAT signaling; MAPK; Tyrosine Kinase/Adaptors |
BMS-599626 (AC480) 是可口服的选择性 HER1和HER2抑制剂,IC50分别为 20 和 30 nM。它对 HER4 的 IC50值为 190 nM,可抑制肿瘤细胞增殖,有治疗肿瘤的潜力。 | |||
T4324 |
PQ401 hydrochloride (196868-63-0(free base))
|
IGF-1R | Tyrosine Kinase/Adaptors |
PQ401 hydrochloride (196868-63-0(free base)) 抑制 IGF-1R 结构域的自磷酸化,IC50 <1 μM。 | |||
T62285 |
Enbezotinib
|
c-RET | Apoptosis; Tyrosine Kinase/Adaptors |
Enbezotinib 是一种能够抑制 RET 自磷酸化的抑制剂。Enbezotinib 能够用于研究癌症。 | |||
T3545 |
RG13022
RG 13022,Tyrphostin RG13022 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
RG13022 (Tyrphostin RG13022) 是一种酪氨酸激酶抑制剂,抑制EGF 受体自身磷酸化的IC50值为4 μM。 | |||
T3654 |
APY29
|
IRE1 | Cell Cycle/Checkpoint |
APY29 是 IRE1α 的变构调节剂;抑制 IRE1α 自磷酸化,IC50值为 280 nM,并激活 IRE1α RNase 活性。 | |||
T16550 |
PKR-IN-C16
|
Others | Others |
PKR-IN-C16 是一种特异性蛋白激酶抑制剂。它能够抑制 PKR 的自磷酸化,解除 PKR 在原代神经元细胞培养中诱导的翻译阻断。 | |||
T3042 |
JAK2 Inhibitor V
JAK2 Inhibitor V Z3,Z3,NSC42834 |
JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells |
JAK2 Inhibitor V (JAK2 Inhibitor V Z3) 是一种新型的 Jak2 特异性抑制剂,以剂量依赖性方式抑制 Jak2-V617F 和 Jak2-WT 自磷酸化。 | |||
T67779 |
Compound TPX-0046
|
c-RET | Apoptosis; Tyrosine Kinase/Adaptors |
Compound TPX-0046 是有效的RET 的抑制剂。化合物TPX-046可以抑制RET 的自磷酸化。 | |||
T9650 |
AZ12672857
|
Src; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
AZ12672857 是一种 EphB4 抑制剂,IC50 为 1.3 nM。 AZ12672857 抑制 Src 转染 3T3 细胞的细胞增殖,IC50 为 2 nM,抑制转染 CHO-K1 细胞中 EphB4 的自磷酸化,IC50 为 9 nM。 | |||
T4053 |
AST 487
NVP-AST 487 |
VEGFR; FLT; c-RET; Bcr-Abl; c-Kit | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
AST 487 (NVP-AST 487) 是 RET 激酶抑制剂 (IC50:880 nM),能够抑制 RET 自磷酸化,及下游效应器激活,也抑制 Flt-3 (IC50:520 nM)。 | |||
T7119 |
Y15
1,2,4,5-苯四胺四盐酸盐,1,2,4,5-Benzenetetramine tetrahydrochlor,FAK Inhibitor 14 |
FAK | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Y15 (1,2,4,5-Benzenetetramine tetrahydrochlor) 是一种特异性的粘着斑激酶抑制剂,能够降低其自身磷酸化活性,抑制癌细胞的活力,阻断肿瘤生长。 | |||
T6619 |
Desmethyl Erlotinib hydrochloride
OSI420,OSI-420,DesMethyl Erlotinib (CP-473420) HCl,去甲厄洛替尼,CP-473420,Desmethyl Erlotinib,OSI 420 |
EGFR; Drug Metabolite | Angiogenesis; JAK/STAT signaling; Metabolism; Tyrosine Kinase/Adaptors |
Desmethyl Erlotinib hydrochloride (OSI 420) 是 Erlotinib 的活性代谢物。Erlotinib 是 EGFR 酪氨酸激酶抑制剂。 | |||
T11569 |
HKI-357
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
HKI-357 是一种不可逆的 EGFR 和ERBB2双重抑制剂,IC50分别为 34 nM 和 33 nM。HKI-357 抑制 EGFR 自磷酸化 (Y1068位点),及 MAPK 和AKT 磷酸化。 | |||
T2693 |
AG1024
Tyrphostin AG 1024,Tyrphostin,AGS 200 |
Apoptosis; IGF-1R | Apoptosis; Tyrosine Kinase/Adaptors |
AG1024 (Tyrphostin) 是一种可逆的,竞争性和选择性的胰岛素样生长因子-1 受体抑制剂,IC50为 7 μM。它抑制胰岛素受体的磷酸化,IC50值为 57 μM。它诱导细胞凋亡并具有抗癌活性。 | |||
T23128 |
PD180970
PD 180970 |
Bcr-Abl; Src; c-Kit | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PD180970 是一种 Bcr-Abl 抑制剂,对于 p210Bcr-Abl、Src 和 Kit 的自磷酸化,IC50 分别为 5 nM、0.8 nM 和 50 nM。 PD180970 可用于慢性粒细胞白血病的研究。 | |||
T3599 |
BFH772
BFH-722 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BFH772 是 VEGFR2抑制剂(IC50:3 nM),具有口服活性。 | |||
T6337 |
RepSox
ALK5 Inhibitor II,SJN 2511,E-616452 |
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
RepSox (ALK5 Inhibitor II) 是一种 TGFβR-1/ALK5 的抑制剂,可以抑制 ATP 与 ALK5 结合 以及 ALK5 自磷酸化 (IC50=23/4 nM),具有选择性。RepSox 可以诱导 MEFs 细胞的脂肪生成。 | |||
T6184 |
Orantinib
SU6668,TSU-68,NSC 702827 |
Apoptosis; VEGFR; FGFR; PDGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Orantinib (NSC 702827) 是一种多靶点受体酪氨酸激酶抑制剂,对 Flt-1、PDGFRβ和FGFR1的Ki 值分别为 2.1 μM、8 nM 和 1.2 μM。 | |||
T30855 |
CGP77675
CGP-77675,1-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenethyl)piperidin-4-ol,ZINC1488120,CGP 77675 |
EGFR; VEGFR; Bcr-Abl; Src | Angiogenesis; Cytoskeletal Signaling; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
CGP77675 (ZINC1488120) 是一种有效的选择性 Src 家族激酶抑制剂,IC50 为 5-20 和 40 nM,用于肽底物的磷酸化和纯化的 Src 的自磷酸化。 CGP77675 具有抗癌活性。 | |||
T3691 |
(Rac)-SAR131675
SAR131675 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
(Rac)-SAR131675 是一种有效的、选择性的VEGFR3抑制剂,其IC50=23 nM。 | |||
T2066 |
Quizartinib
AC220,奎扎替尼 |
Apoptosis; FLT; Autophagy; Ligands for Target Protein for PROTAC | Angiogenesis; Apoptosis; Autophagy; PROTAC; Tyrosine Kinase/Adaptors |
Quizartinib (AC220) 是一种第二代 Ⅱ 型 FLT3 酪氨酸激酶抑制剂,具有口服活性和高选择性,抑制 FLT3-WT 和 FLT3-ITD 自磷酸化 (IC50=4.1/1.1 nM)。Quizartinib 可以诱导肿瘤细胞凋亡。 | |||
T70568 |
H-1356
|
Others | Others |
H-1356 is an insulin-like growth factor 1(IGF-I) analog that inhibits autophosphorylation of IGF-I receptor. | |||
T22462 | 1,2,3,4,5,6-Hexabromocyclohexane | Others | Others |
The compound effectively and directly inhibits JAK2 tyrosine kinase autophosphorylation and specifically inhibits ligand-dependent JAK2 activation. It has no cytotoxicity at 100 μM. A 16-hour treatment with compound (1 μM) decreases JAK2 tyrosine autophos | |||
T69863 |
Dihydrogenistein
|
Others | Others |
Dihydrogenistein is a derivative of Genistein -- a compound that exhibits specific inhibitory activity against tyrosine kinases including autophosphorylation of epidermal growth factor receptor kinase. | |||
T69260 |
Genistein Diglucuronide
|
Others | Others |
Genistein Diglucuronide is a metabolite of Genistein which exhibits specific inhibitory activity against tyrosine kinases including autophosphorylation of epidermal growth factor receptor kinase. | |||
T68360 |
HKI-357 dimaleate
|
Others | Others |
HKI-357 dimaleate is an irreversible dual inhibitor of EGFR and ERBB2. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN1549 |
Damnacanthal
丹宁卡 |
IL Receptor; Akt; Syk | Angiogenesis; Cytoskeletal Signaling; Immunology/Inflammation; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Damnacanthal possesses anti-cancer, immunomodulatory, antinociceptive and anti-inflammatory actions, it can treat or prevent hepatocellular carcinoma through its inhibitory effects on the HGF/c-Met axis. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00774 |
TrkA Protein, Human, Recombinant (aa 33-417, His)
TrkAI,TrkA I,Trk-A,TRKA,NTRK1,MTC,TRK,TrkA-I |
Human | HEK293 Cells |
TrkA, a tyrosine kinase receptor, is an essential component of the nerve growth factor (NGF) response pathway. The binding of NGF to the receptor induces receptor autophosphorylation and activation of intracellular signaling pathways, resulting in diverse biological effects. | |||
TMPJ-00290 |
GFR Alpha-2/GFRA2 Protein, Human, Recombinant (hFc & His)
TRNR2,GDNFR-beta,TGF-β-related neurotrophic factor receptor ... |
Human | HEK293 Cells |
GDNF family receptor alpha-2 is a glycosylphosphatidylinosito l (GPI)-linked cell surface receptor. It is part of the GDNF receptor family. Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) are two structurally related, potent neurotrophic factors that play key roles in the control of neuron survival and differentiation. GFRA2 mediates the NRTN-induced autophosphorylation and activation of the RET receptor. It also able to mediate GDNF signaling through the RET tyrosine kina... | |||
TMPH-02194 |
TAB2 Protein, Human, Recombinant (His & Myc)
Mitogen-activated protein kinase kinase kinase 7-interacting... |
Human | Baculovirus Insect Cells |
Adapter required to activate the JNK and NF-kappa-B signaling pathways through the specific recognition of 'Lys-63'-linked polyubiquitin chains by its RanBP2-type zinc finger (NZF). Acts as an adapter linking MAP3K7/TAK1 and TRAF6 to 'Lys-63'-linked polyubiquitin chains. The RanBP2-type zinc finger (NZF) specifically recognizes Lys-63'-linked polyubiquitin chains unanchored or anchored to the substrate proteins such as RIPK1/RIP1: this acts as a scaffold to organize a large signaling complex to ... | |||
TMPY-03456 |
SRFBP1 Protein, Human, Recombinant (His & GST)
STRAP,BUD22,P49,serum response factor binding protein 1,p49/... |
Human | Baculovirus Insect Cells |
SRFBP1 contains 7 WD repeats and belongs to the WD repeat STRAP family. SRFBP1 may play a role in the cellular distribution of the SMN complex. The SMN complex plays an essential role in spliceosomal snRNP assembly in the cytoplasm and is required for pre-mRNA splicing in the nucleus. SRFBP1 negatively regulates TGF-beta signaling but positively regulates the PDPK1 kinase activity by enhancing its autophosphorylation and by significantly reducing the association of PDPK1 with 14-3-3 protein. SRF... | |||
TMPY-04406 |
Protein Kinase D2/PRKD2 Protein, Human, Recombinant (His & GST)
protein kinase D2,nPKC-D2,PKD2,HSPC187 |
Human | Baculovirus Insect Cells |
Serine/threonine-protein kinase D2, also known as PRKD2 and PKD2, is a cytoplasm and membrane protein that belongs to the protein kinase superfamily, CAMK Ser/Thr protein kinase family and PKD subfamily. PRKD2 / PKD2 is widely expressed. It contains one PH domain, two phorbol-ester/DAG-type zinc fingers and one protein kinase domain. PRKD2 / PKD2 is activated by DAG and phorbol esters. Phorbol-ester/DAG-type domains bind DAG, mediating translocation to membranes. Autophosphorylation of Ser-71 an... | |||
TMPY-04403 |
NLK/Nemo Like Kinase Protein, Human, Recombinant (His & GST)
nemo-like kinase,LAK1 |
Human | Baculovirus Insect Cells |
Nemo-like kinase contains 1 protein kinase domain and belongs to the protein kinase superfamily, CMGC Ser/Thr protein kinase family, and MAP kinase subfamily. It also contains a TQE activation loop motif in which autophosphorylation of the threonine residue (Thr-298) is sufficient for kinase activation. As a serine/threonine-protein kinase, Nemo-like kinase regulates some transcription factors with key roles in cell fate determination. It is a positive effector of the non-canonical Wnt signaling... | |||
TMPY-04412 |
Germinal Center Kinase/MAP4K2 Protein, Human, Recombinant (His & GST)
mitogen-activated protein kinase kinase kinase kinase 2,GCK,... |
Human | Baculovirus Insect Cells |
Mitogen-activated protein kinase kinase kinase kinase 2, also known as B lymphocyte serine/threonine-protein kinase, Germinal center kinase, MAPK/ERK kinase kinase kinase 2, MEK kinase kinase 2, Rab8-interacting protein, and MAP4K2, is cytoplasm and peripheral membrane protein that belongs to the protein kinase superfamily, STE Ser/Thr protein kinase family and STE2 subfamily. MAP4K2 contains one CNH domain and one protein kinase domain. Although this kinase is found in many tissues, its express... | |||
TMPY-04555 |
GRK5 Protein, Human, Recombinant (His)
G protein-coupled receptor kinase 5,GPRK5 |
Human | Baculovirus Insect Cells |
G protein-coupled receptor kinase 5, also known as G protein-coupled receptor kinase GRK5 and GRK5, is a member of the protein kinase superfamily, AGC Ser/Thr protein kinase family, and GPRK subfamily. GRKs specifically phosphorylate agonist-occupied G protein-coupled receptors at the inner surface of the plasma membrane (PM), leading to receptor desensitization. GRKs utilize a variety of mechanisms to bind tightly, and sometimes reversibly, to cellular membranes. GRKs play an important role in ... | |||
TMPY-04260 |
p38 Protein, Human, Recombinant (His)
mitogen-activated protein kinase 14,CSPB1,PRKM14,RK,p38α,CSB... |
Human | Baculovirus Insect Cells |
MAPK14 contains 1 protein kinase domain and belongs to the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation, and development. MAPK14 can be detected in the brain, heart, placenta, pancreas, and skeletal muscle and it is expressed to a lesser extent in the lung, liver, and kidney. MAPK14 is activated by various environmental stresses ... | |||
TMPY-04456 |
PKC nu Protein, Human, Recombinant (GST)
PRKCN,nPKC-NU,PKC-NU,PKD3,EPK2,protein kinase D3 |
Human | Baculovirus Insect Cells |
Serine/threonine-protein kinase D3, also known as Protein kinase C nu type, Protein kinase EPK2, PRKD3, EPK2 and PRKCN, is a cytoplasm and membrane protein that belongs to the protein kinase superfamily, CAMK Ser/Thr protein kinase family and PKD subfamily. PRKD3 / PRKCN contains one PH domain, two phorbol-ester/DAG-type zinc fingers and one protein kinase domain. Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second ... | |||
TMPH-02274 |
JAK2 Protein, Human, Recombinant (His)
JAK2,Janus kinase 2,Tyrosine-protein kinase JAK2 |
Human | E. coli |
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple int... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T19119 |
3-Hydroxy Midostaurin-D5
CGP52421-D5 |
Others | Others |
3-Hydroxy Midostaurin-D5 (CGP52421-D5) is a deuterium-labeled 3-Hydroxy Midostaurin which is a metabolite of PKC412. PKC412 effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation (IC50s: 132 nM and 9.8 μM in culture medium and plasma). | |||
T35915 |
Erlotinib-13C6
Erlotinib-13C6 |
||
Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1]. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process[2]... |